GSK plc Files 6-K for PDMR Shareholding Notification
Ticker: GLAXF · Form: 6-K · Filed: Dec 23, 2024 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Dec 23, 2024 |
| Risk Level | low |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $33.8097 |
| Sentiment | neutral |
Sentiment: neutral
Topics: insider-notification, shareholding, director-dealings
Related Tickers: GSK
TL;DR
GSK plc files 6-K: Lady Susan Symonds (PCA to Chair) notified about shareholding. Details TBD.
AI Summary
On December 23, 2024, GSK plc filed a Form 6-K reporting a transaction notification. Lady Susan Symonds, a person closely associated with Sir Jonathan Symonds (Non-Executive Chair), made an initial notification regarding shareholding. The filing does not specify the nature or volume of the transaction.
Why It Matters
This filing provides transparency into the shareholding activities of individuals closely associated with key executives at GSK plc, which can be relevant for investors monitoring insider transactions.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of shareholding notification by a person associated with a director and does not indicate any immediate financial or operational risk.
Key Players & Entities
- GSK plc (company) — Registrant
- Lady Susan Symonds (person) — PCA of Non-Executive Chair
- Sir Jonathan Symonds (person) — Non-Executive Chair
- December 2024 (date) — Reporting period
- 20241223 (date) — Filing date
FAQ
What type of transaction did Lady Susan Symonds notify GSK plc about?
The filing indicates an 'Initial notification' regarding 'Director/PDMR Shareholding' for Lady Susan Symonds, who is a PCA of Sir Jonathan Symonds, but the specific nature of the transaction is not detailed in this excerpt.
Who is Sir Jonathan Symonds in relation to GSK plc?
Sir Jonathan Symonds is the Non-Executive Chair of GSK plc.
What is the filing form and its purpose?
The filing is a Form 6-K, which is a Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934, used to report material information that the company has made public in its home country.
When was this Form 6-K filed?
This Form 6-K was filed on December 23, 2024.
Does this filing indicate any change in GSK plc's financial performance?
No, this filing is a transaction notification related to director/PDMR shareholding and does not contain information about GSK plc's financial performance.
Filing Stats: 1,808 words · 7 min read · ~6 pages · Grade level 18.3 · Accepted 2024-12-23 12:53:53
Key Financial Figures
- $33.8097 —   Volume(s)     $33.8097   272     

Filing Documents
- a1582r.htm (6-K) — 208KB
- 0001654954-24-015843.txt ( ) — 209KB
SIGNATURES
SIGNATURES     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.   GSK plc   (Registrant)     Date: December 23, 2024         By:/s/ VICTORIA WHYTE --------------------------       Victoria Whyte   Authorised Signatory for and on   behalf of GSK plc